Dehydroergotamine for Acute Moderate-to-Severe Migraine When Triptans Fail or Are Contraindicated
Dihydroergotamine (DHE) is a highly effective second-line parenteral option for acute moderate-to-severe migraine when triptans are ineffective or contraindicated, with intravenous administration providing superior efficacy compared to intranasal formulations. 1, 2, 3
FDA-Approved Indications
- DHE is FDA-approved for the acute treatment of migraine with or without aura and for acute cluster headache episodes. 2
Dosing and Administration Routes
Intravenous (IV) Administration – Preferred Route
- Initial dose: 1 mg IV at the onset of migraine attack. 2
- May repeat at 1-hour intervals to a maximum total dose of 2 mg IV per 24 hours. 2
- Peak concentration occurs within 6 minutes with IV administration, providing the fastest onset among all DHE formulations. 3
- IV DHE demonstrates superior efficacy compared to intramuscular, subcutaneous, or intranasal routes. 3
Intramuscular (IM) or Subcutaneous (SC) Administration
- Initial dose: 1 mg IM or SC. 2
- May repeat at 1-hour intervals to a maximum total dose of 3 mg per 24 hours for IM/SC routes. 2
- Peak concentration occurs in 34 minutes (IM) or 56 minutes (SC). 3
Intranasal Administration
- 2 mg intranasal spray is the recommended dose, providing slightly superior pain relief and fewer adverse events compared to 3 mg. 4
- 27% of patients achieve headache resolution (no pain or mild pain) within 30 minutes; 70% by 4 hours. 4
- Intranasal DHE is generally more effective than placebo but less effective than sumatriptan. 3
- Peak concentration occurs in 56 minutes with intranasal administration. 3
- Headache recurrence within 24 hours occurs in only 14% of patients whose headaches resolved. 4
Maximum Weekly Dosage
- Total weekly dosage must not exceed 6 mg across all routes of administration. 2
- DHE should not be used for chronic daily administration. 2
Absolute Contraindications
Cardiovascular and Vascular Contraindications
- Ischemic heart disease, previous myocardial infarction, or coronary artery vasospasm. 2
- Uncontrolled hypertension. 1, 2
- Cerebrovascular disease, history of stroke or TIA. 2
- Peripheral vascular disease or Raynaud's syndrome. 2
Concurrent Medication Contraindications
- Concurrent use of triptans within 24 hours (additive vasoconstrictive effects). 2
- Concurrent use of peripheral vasoconstrictors (synergistic blood pressure elevation). 2
- Concurrent use of beta-blockers (propranolol may potentiate vasoconstrictive action). 2
- Concurrent use of CYP3A4 inhibitors (macrolide antibiotics, protease inhibitors). 2
Other Absolute Contraindications
- Pregnancy (increased risk of preterm delivery). 2
- Sepsis. 1
- Pheochromocytoma. 2
- Seizure disorders. 2
- Active gastrointestinal bleeding or obstruction. 2
Relative Contraindications and Precautions
- Nicotine use may provoke vasoconstriction and predispose to greater ischemic response. 2
- Oral contraceptives: The effect on DHE pharmacokinetics has not been studied. 2
- SSRIs: Weakness, hyperreflexia, and incoordination have been reported rarely when 5-HT₁ agonists are co-administered with SSRIs. 2
Adverse Effects and Monitoring
Common Adverse Effects
- Nausea is the most common adverse effect, particularly with parenteral formulations; it is significantly less frequent with intranasal dosing. 3, 4
- Adverse events related to intranasal administration include nasal discomfort, rhinitis, and altered taste. 4
- Adverse effects due to adrenergic and dopaminergic receptor binding are significantly less with orally inhaled DHE compared to IV DHE at therapeutically effective doses. 3
Serious Adverse Effects Requiring Immediate Reporting
- Numbness or tingling in fingers and toes. 2
- Muscle pain in arms and legs. 2
- Weakness in legs. 2
- Chest pain. 2
- Temporary speeding or slowing of heart rate. 2
- Swelling or itching. 2
Monitoring Requirements
- Patients should be evaluated for symptoms or signs suggestive of decreased arterial flow, including ischemic bowel syndrome or Raynaud's syndrome. 2
- Cardiovascular evaluation is warranted if patients experience chest pain, weakness, or other vasoconstrictive symptoms. 2
Clinical Positioning in Treatment Algorithm
When to Use DHE
- DHE is recommended as a second-line option when triptans are contraindicated (cardiovascular disease, uncontrolled hypertension) or have failed after adequate trials. 1, 5
- IV DHE is the preferred parenteral option for severe migraine attacks requiring emergency department or urgent care treatment when triptans cannot be used. 1
- DHE is particularly useful for status migrainosus (migraine lasting >72 hours). 5, 6
Combination with Antiemetics
- Administer IV metoclopramide 10 mg or prochlorperazine 10 mg 20–30 minutes before DHE to prevent nausea and provide synergistic analgesia. 1
Medication-Overuse Headache Prevention
- Limit DHE use to ≤2 days per week (≤10 days per month) to prevent medication-overuse headache. 5
- If a patient requires acute treatment more than twice weekly, initiate preventive therapy immediately rather than increasing DHE frequency. 5
Critical Pitfalls to Avoid
- Never administer DHE within 24 hours of triptan use due to additive vasoconstrictive effects. 2
- Do not use DHE in patients with uncontrolled hypertension or cardiovascular disease, as it can cause coronary artery vasospasm. 2
- Avoid chronic daily administration of DHE, as it is intended only for acute treatment. 2
- Do not co-administer DHE with beta-blockers, as propranolol may potentiate vasoconstrictive action. 2
- Ensure patients report any symptoms of decreased arterial flow immediately (numbness, muscle pain, chest pain). 2
Special Populations
Pregnancy
- Avoid DHE during pregnancy due to increased risk of preterm delivery. 2
- Acetaminophen 1000 mg is the preferred first-line acute treatment during pregnancy. 7
Women of Childbearing Potential
- Discuss potential adverse effects of DHE during pregnancy before initiating therapy to enable safe treatment planning. 7
Alternative Options When DHE Is Contraindicated
- CGRP antagonists (ubrogepant, rimegepant) are third-line options when both triptans and DHE are contraindicated. 1
- Lasmiditan (5-HT₁F agonist) is a non-vasoconstrictive alternative for patients with cardiovascular contraindications. 1
- IV metoclopramide 10 mg + IV ketorolac 30 mg is an effective combination for severe migraine when DHE is contraindicated. 1
Evidence Quality Summary
- Level A evidence supports the efficacy of IV DHE for acute migraine treatment. 1, 5
- Level B evidence supports the efficacy of intranasal DHE, though it is less effective than triptans. 3, 4
- High-quality randomized controlled trials demonstrate that intranasal DHE is more effective than placebo but less effective than sumatriptan. 3, 4